UllrichLab

Great time at joint 🇫🇷🇩🇪 #NK#ILC meeting in Lyon! Honored to receive an oral presentation award. Fun catching up with old friends from 🇸🇪 🇺🇸 and meeting new ones. Huge thanks for an insightful meeting! Think we all found gold of knowledge at the end of the rainbow! 🐓🌈🧫🧬🍇😉

Online Now: Targeting HLA-E-overexpressing cancers with a NKG2A/C switch receptor dlvr.it/TFV5VC

Congratulations! The #DGGTeV proudly awards @TobiasBexte representing the @Ullrich_Lab at @goetheuni the #PoQ2024Q2 for harnessing SB-technology for virus-free engineering of primary NK cells to improve their basal anti-cancer function via CAR introduction dg-gt.de/paper-of-the-q…

🔍 Highlights from Keynote Lecture 1 🔴 No one less than the Nobel Prize Winner 2018, James P. Allison, on immune checkpoint blockade therapy at #ECI2024 🎉 🔑Key points: 💡Anti-CTLA-4 therapy creates a “hot” tumor, which does not happen with anti-PD1 therapy. 🔬Anti-CTLA-4 therapy results in a phenotypical switch inducing ICOS+ Th1-like CD4 T cells. ICOS/ICOSL pathway is necessary for optimal anti-tumor response. A profound thanks to James P. Allison for his groundbreaking contributions 👏👏 #Immunology #Dublin

I had an amazing time visiting and giving a talk at Frankfurt University ⁦⁦@goetheuni⁩ hosted by ⁦@EvelynNKlab2012⁩ who is doing some cutting edge NK cell work. Also was fun to meet faculty and students there.

Happy to share our new NK cell resource in @NatImmunol: "Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping." nature.com/articles/s4159…. @herknet, @AlinePfefferle, @AmirHorowitz @humancellatlas, @CoE_PRIMA, @UniOslo_MED

Thrilled to announce the publication of our latest research in Nature Immunology. Joining forces with 20 laboratories in Europe and USA, we identified the three prominent NK cell subsets in human: NK1, NK2, and NK3: rdcu.be/dMuAs

Many congratulations to our Dr. Sunil Acharya @sunilacharya13 for his exciting research on CD70-targeting CAR NK cells, published in Cancer Discovery! Sunil and his co-authors showed that the incorporation of CD28 costimulation, which is normally absent in NK cells, in the CAR construct improves efficacy of CAR NK cells via the LCK/CD3ζ/ZAP70 pathway. Sincere thanks to our collaborators for their invaluable contributions. We’re excited about the promising clinical trials ahead! @MDAndersonNews #CancerResearch #Immunotherapy #CAR_NKCells @kchenken @UH_NVLab

Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors dlvr.it/T6w0bs #genetherapy #celltherapy